ASX share prices are regularly changing and that gives brave investors the chance to buy great investments at a much cheaper valuation.
I don’t know how long share prices will be as low (or lower) than they are right now. It could be a few weeks if everything goes back to normal in the Middle East, or it could take longer if inflation impacts are longer-term.
Either way, I think it’s a good idea to invest when share prices are lower, such as right now.
Pro Medicus Ltd (ASX: PME)
Pro Medicus may well be one of the best businesses on the ASX with its full range of medical imaging software and services for clients across places like Europe, the US and Australia.
Its underlying EBIT (EBIT explained) margin has increased to 72.6% as of the HY26 result, which is one of the highest on the ASX.
This means almost three-quarters of its new revenue is turning into EBIT which is largely translating into a larger dividend as well as an improving balance sheet.
HY26 saw revenue jump 28.4% to $124.8 million and the underlying profit before tax grew 29.7% to $90.7 million. That shows its profit margins continue to increase, helping the ASX share’s interim dividend per share jump 28% to $0.32.
Despite all of those positives, ongoing contract wins, contract renewals at a higher fee and expansion of its cardiology offering, the Pro Medicus share price has dropped more than 60% since September 2025.
The Pro Medicus share price is now valued at 80x the estimated earnings for FY26, according to the projection on Commsec.
VanEck Morningstar Wide Moat ETF (ASX: MOAT)
This exchange-traded fund (ETF) is a business we can buy just like any ASX share.
The idea is that it invests in US shares that have the strongest economic moat, or competitive advantages.
Think about the sorts of advantages businesses we use in our everyday life have – network effects, brand power, intellectual property, cost advantages and so on. This is what enables the companies to generate strong profits and could enable ongoing profit growth.
The MOAT ETF looks to own businesses with competitive advantages that are expected to last for at least two decades, making the ETF itself an excellent idea for a long-term investment.
But, the MOAT only invests in these great businesses when the valuation looks attractive compared to how much Morningstar analysts think the business is worth.
It currently has 57 holdings with its largest holdings being Bristol-Myers Squibb, Mondelez, Constellation Brands and Kenvue. I like the diversification that the fund can provide.
I think it’s impressive that the MOAT ETF has returned an average of 15.3% per year over the last ten years.
